Jasper Therapeutics, Inc. — Form 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated January 3, 2024, reports a corporate action by Jasper Therapeutics, Inc., a Delaware corporation listed on Nasdaq under JSPR. The filing does not provide operating or financial results for a reporting period.
Material Corporate Action
- The Company filed a Certificate of Second Amendment to its Second Amended and Restated Certificate of Incorporation to effect a 1-for-10 reverse stock split of its voting common stock.
- The reverse split became effective at 12:01 a.m. Eastern Time on January 4, 2024, with split-adjusted trading expected to begin at market open that day.
- The trading symbol remained JSPR; the post-split common stock CUSIP became 471871202.
- Every 10 pre-split common shares were combined into one post-split share. The par value remained $0.0001 per share.
- Proportionate voting and other shareholder rights were generally unchanged, except for de minimis effects from eliminating fractional shares. Cash will be paid for fractional shares based on the January 3, 2024 Nasdaq closing price.
- The reverse split also applies to shares issuable under outstanding warrants, stock options, and equity incentive plans, with proportional adjustments to share amounts and exercise prices.
- For publicly traded warrants under JSPRW, every 10 pre-split warrants became exercisable for one common share at an exercise price of $115.00 per share, compared with $11.50 before the split.
Financial Metrics and Liquidity
The filing does not provide revenue, profit or loss, cash flow, margins, debt, cash balances, liquidity measures, or other financial results.
Purpose, Outlook, and Risks
The stated purpose of the reverse stock split was to help the Company regain compliance with Nasdaq’s minimum bid price requirement of $1.00 per share. The filing does not provide financial guidance, operating forecasts, management commentary on performance, or additional contingencies.
Important Facts to Verify
- Confirm the January 4, 2024 effective date and Nasdaq commencement of split-adjusted trading.
- Verify the post-split share count and any resulting changes in ownership or outstanding securities in subsequent filings.
- Confirm the Company’s Nasdaq minimum bid price compliance status after the reverse split.
- Review the treatment of fractional shares and any cash payments to registered holders.
- Verify the proportional adjustments to outstanding options, warrants, and equity incentive plan reserves.
- Review Exhibit 3.1, the filed Certificate of Amendment, for the complete legal terms.